Around 30 percent of the population will experience herpes zoster (HZ), 10 percent of whom develop postherpetic neuralgia (PHN). Together, these illnesses produce a significant economic burden to the healthcare system. Friesen, et al. (2017) analyzed administrative healthcare data collected over the period of April 1, 1997 to March 31, 2014 to determine the healthcare system burden of HZ using direct medical costs. Episodes of HZ were identified using international classification of disease (ICD) codes. Trends in age-adjusted (AA) HZ-rates were analyzed by piecewise-regression. Total annual and per-episode costs were determined for drug treatment, medical care and hospitalizations within each year.
The incidence of HZ increased by 49.5 percent from 1997/98 to 2013/14. Piecewise-regression of AA-rates revealed a steady AA-rate of 4.7 episodes/1000 person-years (PY) from 1997/98 to a breakpoint in 2008/09, after which rates began to increase reaching 5.7 episodes/1000 PY in 2013/14.
Drug costs rose significantly (p <0.03) from $89.77/episode (95% CI: $82.96, $96.59) to $127.34/episode (95% CI: $117.24, $137.44). Medical costs increased (p <0.0001) from $57.98/episode (95% CI; $55.26, $60.70) to $78.84/episode (95% CI; $74.08, $83.61). Hospitalization rates declined from 3.10% in 1997/98 to 1.36% in 2011/12, resulting in cost dropping from $397/episode (95% CI; $284, $511) to $195/episode (95% CI; $129, $260).
Total annual costs of HZ and PHN were $1,997,183 in 2011/12, 4.7 percent lower than the 1997/98 costs of $2,095,633.
The researchers concluded that a significant increase in annual number of HZ cases was observed, driven largely by demographic factors. A 21 percent increase in the AA-incidence reveals changes in HZ rates beyond those expected by population shifts. The large increase in incidence of HZ, with rising per episode medical and prescription costs were offset by dramatic drops in hospitalization rates, the net effect of which has been to hold the total costs relatively constant. However, the decrease in hospitalization rates slowed over the last half of the study, settling at 1.3 percent in the last four study years. The likely future of HZ burden is one of rising costs, primarily driven by the demographic shifts of an increasing and aging population.
Reference: Friesen KJ, et al. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia. BMC Infectious Diseases. 2017;17:69
Undermining Public Health: Nearly 1300 Cut From CDC With More to Come
February 14th 2025The Trump administration’s decision to terminate nearly 1,300 CDC employees weakens America’s public health defenses, jeopardizes critical research, and endangers the nation’s preparedness for future health crises.
Infection Intel: GermZapp Is the Innovative Hand Hygiene System IPC Needs
February 14th 2025GermZAPP is an affordable hand hygiene system designed to educate, monitor, and encourage adherence in schools, nursing homes, and health care settings, effectively addressing gaps in infection control.
Strengthening Infection Prevention: APIC Urges Support From HHS Secretary Kennedy
February 13th 2025APIC congratulates Secretary Robert F. Kennedy, Jr on his appointment and urges support for infection prevention priorities, including NHSN funding, workforce development, nursing home IPC improvements, medical device cleaning standards, and global health collaboration.
Universities and States Sue NIH Over Funding Cuts, Federal Judge Temporarily Halts Policy
February 13th 2025Twelve universities and 3 education groups filed a lawsuit against the NIH and HHS, challenging a 15% cap on research grant funding. A federal judge issued a temporary restraining order, halting the cuts while litigation proceeds. A hearing is set for February 21, 2025, and states and institutions are pushing for permanent relief.